ANI Pharmaceuticals Reports First Quarter 2019 Results and Reaffirms Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
ANI Pharma (ANIP) Tops Q1 EPS by 25c, Revenues Beat; Reaffirms FY19 Revenue Outlook
May 9, 2019 8:33 AM EDTANI Pharma (NASDAQ: ANIP) reported Q1 EPS of $1.30, $0.25 better than the analyst estimate of $1.05. Revenue for the quarter came in at $52.9 million versus the consensus estimate of $50.57 million.
Net revenues of $52.9 million, an increase of 14% versus 2018GAAP net income of $0.4 million and diluted GAAP earnings per share of... More